History.. iCo-009 - Fungal & Parasitic Infections ~$1B+. Also represents a new drug delivery technology with the potential to reprofile other IV administered drugs to the oral route of administration.
AmpB works, its been around since the fifties and is the standard against which all other drugs in this class are measured. The problem with the drug is how it was delivered. It now seems a self-administered (no hospital stay, no toxicity issues), oral formulation of AmpB is attainable. 009 is late pre-clinical stage. The next steps are to complete pre- clinical toxicology studies and then launch a Phase 1 safety trial.
... Therapeutics ICO-TSX.v. So what exactly does iCo Therapeutics have in their pipeline that's got me so excited? ... AmpB has for many years been the gold standard for systemic antifungal drugs. AmpB formulated for IV ...